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 38 
Abstract  39 
 40 
Impulse oscillometry (IOS) is the most commonly used type of forced oscillation 41 
technique in clinical practice, although relatively little is known about its application in 42 
COPD.  Resistance at 20Hz (R20) is unrelated to COPD severity and does not 43 
improve with bronchodilatation or bronchoconstriction, inferring a lack of large airway 44 
involvement in COPD. Peripheral airway resistance expressed as frequency 45 
dependent heterogeneity between 5Hz and 20Hz (R5-R20), and peripheral airway 46 
compliance as area under the reactance curve (AX), are both closely related to 47 
COPD severity and exacerbations.  Both R5-R20 and AX markedly improve in 48 
response to long acting bronchodilators, while AX appears to be more sensitive than 49 
R5-R20 in response to bronchoconstriction. 50 
Future studies may be directed to assess if IOS in combination with spirometry is 51 
more sensitive at predicting future exacerbations. Perhaps AX might also be useful 52 
as a screening tool in early stage disease or to monitor long term decline in COPD.  53 
 54 
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Abbreviations: 75 
 76 
AX: Area Under reactance curve between 5Hz and resonant frequency 77 
COPD: Chronic obstructive pulmonary disease 78 
FEF25-75: Forced expiratory flow between 25 and 75% 79 
FEV1: Forced expiratory volume in 1 second 80 
FVC: Forced vital capacity 81 
FOT: Forced oscillation technique 82 
Fres: Resonant Frequency 83 
GOLD: Global Initiative for Chronic Obstructive Lung Disease 84 
HRCT: High resolution CT scanning  85 
IOS: Impulse oscillometry 86 
R: Resistance  87 
R5: Resistance at 5Hz 88 
R20: Resistance at 20Hz  89 
R5-R20: Heterogeneity of resistance 90 
SRM: Standardised response mean 91 
X: Reactance  92 
X5: Reactance at 5Hz 93 
Z: Impedance 94 
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 112 
Background: 113 
 114 
Current COPD guidelines advocate using spirometry to assess airflow limitation in 115 
conjunction with symptoms and exacerbation history [1]. Spirometry involves a forced 116 
expiratory manoeuvre to measure dynamic lung volumes and expiratory flow. It has 117 
no comparable manoeuvre in real life, and hence is an artificial action. Cooperation 118 
may be difficult especially in patients who are breathless or susceptible to coughing. 119 
The forced expiratory flow between 25 and 75% (FEF25-75) of forced vital capacity 120 
(FVC) is thought to represent dynamic volume dependent small airway closure, but 121 
has marked inherent variability. Hence there is an unmet need for an alternative 122 
more patient friendly method to assess lung function in patients with COPD. 123 
The forced mono-frequency oscillation technique (FOT) was first described  in 1956 124 
by Dubois [2] . Since then several FOT methods have been developed of which 125 
impulse oscillometry (IOS) is most commonly used in every day clinical practice. The 126 
application of IOS has been extensively described in asthma [3] .The purpose of this 127 
article is to critically appraise the potential role of IOS in COPD, where much less is 128 
known. It will focus on the more clinical applications of IOS, as this appertains to the 129 
general pulmonologist. This review will therefore not detail the physics of IOS or 130 
other FOT methods which have been covered elsewhere [4-6].  131 
 132 
Basic principles of impulse oscillometry:  133 
 134 
The currently used method of IOS was originally  detailed in 1976 by Michaelson [7] 135 
and was then commercialised in 1998 [8] , available as the Jaeger Masterscreen IOS  136 
(Hoechberg ,Germany) .It has been widely adopted in paediatric pulmonology, but 137 
less so for adults ,aside as a research tool . IOS propagates a train of bi-directional, 138 
harmonic sound waves along the bronchial tree, from a source such as a 139 
loudspeaker. The oscillations are applied at a fixed square wave frequency of 5Hz, 140 
from which all other frequencies of interest are derived, typically multiples of 5Hz 141 
(between 5 and 35Hz) [9], each impulse lasting between 30 to 40ms . Measurements 142 
are made via a conducting tube to a mouthpiece with the cheeks held to obviate 143 
upper airway shunting. Forced oscillations are superimposed on top of tidal breathing  144 
to assess the frequency (Hz) dependence of the pressure/flow (as kPa/L/s or 145 
cmH2O/L/s) relationship of respiratory impedance (Z), as in phase resistance (R) and 146 
out of phase reactance (X) components. A transducer attached to a 147 
pneumotachograph measures inspiratory and expiratory flow and pressure with 148 
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signal filtering used to separate breathing patterns from pressure and flow. It is 149 
performed using normal tidal breathing over a period of around 30 to 40s, and being 150 
effort independent is more physiological than spirometry. Conventionally the mean of 151 
whole breath values are used rather than separate inspiratory and expiratory 152 
moieties. As in spirometry three technically acceptable IOS manoeuvres are used. 153 
In essence, IOS can be considered as bronchial sonar. Higher frequency waves 154 
travel shorter distances typically reflecting larger airways. Thus the resistance at 155 
20Hz (R20) represents proximal resistance. Lower frequency waves travel further 156 
reaching the smaller airways <2mm in diameter after the eighth generation .Hence 157 
the resistance at 5Hz (R5) represents the total lung resistance. COPD and asthma 158 
will increase total resistance (R5) to a relatively greater degree than proximal 159 
resistance (R20). This is known as a frequency dependent change or heterogeneity 160 
of resistance evident as raised peripheral resistance (R5-R20). Nonetheless further 161 
validation is required to characterise heterogeneity of resistance and its relationship 162 
to the calibre of small and large airways.  163 
Reactance can be considered as the out of phase component of respiratory 164 
impedance (with flow, but not volume), reflecting the balance between inertial and 165 
elastic properties of distensible airways. Typically this is measured at 5Hz (X5) or as 166 
the area under the reactance curve (AX) between 5Hz and the resonant frequency 167 
(RF),the latter representing the point at which opposing inertial and capacitive 168 
components cancel each other out . Conventionally AX is reported as a positive 169 
value for the area under the curve, even though in reality reactance per se becomes 170 
more negative (figure). AX represents low frequency reactance in smaller airways 171 
where elastance exceeds inertance, with increased values reflecting reduced lung 172 
compliance and stiffer lungs (Table). In asthma resistance and reactance tend to 173 
change in proportionate fashion, while in COPD reactance usually alters to a 174 
relatively greater degree than resistance. 175 
IOS therefore provides more detailed information than spirometry on regional lung 176 
function and should be considered as being complementary to spirometry to 177 
comprehensively assess lung function in COPD. For example in patients with 178 
persistent asthma who had a preserved FEV1, the combined use of R5-R20  with 179 
FEF25-75 results in more predictive of impaired  long term asthma control than either 180 
parameter used alone [10]. Although there are no defined reference values for 181 
COPD, we would propose pragmatic IOS cut offs for R5 > 0.5 kPa/L/s (>5.1 182 
cmH2O/L/s), R5-20 > 0.10 kPa/L/s (1.02 cmH2O/L/s), AX > 1.0 kPa/L 183 
(>10.2cmH2O/L) as being abnormal [11, 12]. Further cohort based studies are 184 
required to define proper reference values for COPD and asthma.  185 
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 186 
 187 
Relationship of IOS to disease severity: 188 
 189 
The largest database involving IOS was the ECLIPSE cohort comprising  2054 190 
patients with COPD (GOLD stage 2-4) and 233 healthy controls , in whom high 191 
resolution CT scanning (HRCT) was also performed [11]. R20 values were similar 192 
across GOLD stages 2-4 (0.29, 0.31, 0.31 kPa/L/s), but higher than controls (0.26 193 
kPa/L/s). In contrast R5-R20 increased proportionately from GOLD stage 2 -4 (0.15, 194 
0.20, 0.24 kPa/L/s), compared to controls (0.07kPa/L/s) .This in turn suggests that 195 
smaller rather than larger airways are the main determinant of increased lung 196 
resistance.  197 
For AX there were increasing values across GOLD stages 2-4 (1.37, 2.25, 3.23 198 
kPa/L) which were also higher than controls (0.38 kPa/L) along with a similar pattern 199 
for X5. Comparing GOLD 2 versus 4, equated to a 136% difference in AX and 60% in 200 
R5-20. Hence increased reactance (i.e. reduced compliance) predominates over 201 
increased resistance in relation to increasing COPD severity. There was a poor 202 
degree of correlation between R5-R20 or AX and HRCT low attenuation, inferring 203 
that the degree of emphysema is not closely related to either resistance or 204 
compliance.  205 
In a cohort of 215 patients GOLD stages 1-4 ,values for AX (0.66 ,1.43 ,2.07, 2.5 206 
kPa/L) mirrored the ratio of residual volume to total lung capacity (RV/TLC) 207 
(45.7,51.2,58.1,66.0 %) ,inferring the degree of air trapping is related to reduced lung 208 
compliance [12]. Studies have also shown a relationship between increasing AX and 209 
exacerbation frequency in COPD [11, 12]. A cross sectional evaluation of  94 COPD 210 
patients with moderate COPD revealed the strongest relationships for X5 in relation 211 
to FEV1  and specific airway conductance [13]. Multiple regression analysis of 75 212 
patients with moderate COPD found that R5-R20 and X5 but not R20 were more 213 
closely related to health status and symptoms than either FEV1 or HRCT low 214 
attenuation [14] .In a screening study to detect early COPD , among 124 subjects 215 
who had positive  spirometry criteria ,the presence of self reported symptoms was 216 
associated with higher values of R5-R20 ,X5 and AX [15].  217 
A comparison of  36 asthma patients ,24 COPD patients and 24 healthy subjects 218 
showed values for R5-R20 and X5 in severe asthma were 0.13 kPa/L/s and -0.18 219 
kPa/L/s respectively ; in moderate COPD  0.22 kPa/L/s and X5 -0.27 kPa/L ; and in 220 
controls 0.01 kPa/L/s and  -0.12 kPa/L/s [16]. Thus, patients with COPD have a 221 
relatively higher level of peripheral airway dysfunction compared to those with 222 
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asthma in respect of both resistance and reactance. This is in keeping with 223 
pathological and radiological changes seen in small airways associated with disease 224 
progression in COPD [17, 18] . 225 
 226 
Bronchodilator response and IOS: 227 
 228 
Significantly greater changes were observed for R5 and RF, but not R20 or X5, when 229 
comparing responses to tiotropium 18ug and salmeterol 100ug in 32 patients with 230 
moderate COPD [19] . A trial in 16 patients with moderate COPD evaluated the 231 
effects of 4 weeks with open label tiotropium alone or with the addition of tulobuterol . 232 
Tiotropium alone produced significant improvements versus baseline in AX, R5 and 233 
R5-20, both drugs were better than tiotropium ,while R20 was unchanged [20] . For 234 
example with both drugs there were 56% ,46%  and 38%  changes  in AX ,X5  and 235 
R5-R20 respectively,  as compared to a 16% change in FEV1.  236 
In an open label study 20 patients with moderate COPD received either tiotropium or 237 
glycopyrronium/indacaterol with IOS measured at baseline and 52 weeks [21] . 238 
Compared to baseline there were significant changes in R5, X5 but not R20 with 239 
glycopyrronium /indacaterol, while tiotropium afforded no improvements.  240 
A double blind randomised cross-over trial involved 19 patients with severe COPD 241 
who received tiotropium or placebo for 2 weeks as add on to budesonide/formoterol 242 
combination taken during the preceding 4 weeks[22] . Compared to placebo the first 243 
but not last dose of tiotropium as triple therapy conferred significant improvements in 244 
X5, AX and RF, but not R5 or R20. Specific airways resistance but not RV/TLC also 245 
improved after single but not chronic dosing with tiotropium. 246 
Taken together these data suggest that muscarinic and beta-2 receptors located in 247 
small airways (R5-R20, X5, AX) are relatively more important than large airways 248 
(R20) for mediating bronchodilator responses in COPD. Alternatively one might 249 
speculate that large airways disease per se is less important than small airway 250 
disease in COPD.  Moreover increased lung compliance (as reduced AX values) in 251 
response to bronchodilators may reflect lung deflation, perhaps allowing the patient 252 
to breathe at a better mechanical advantage at a lower RV. 253 
 254 
Bronchoconstrictor response with IOS: 255 
 256 
Methacholine challenge was performed in 10 asthma and 25 moderate to severe 257 
COPD patients to achieve a 20% fall in FEV1. In asthma there was concordance 258 
between effects on resistance and reactance ,as a significant fall in X5 along with a 259 
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significant rise in R5 , while in COPD there was discordance in terms of a significant  260 
change in X5 but not R5 [23] .  261 
12 moderate to severe COPD patients receiving beclometasone/formoterol 262 
combination at baseline were given the non selective beta-blocker carvedilol 263 
,followed by formoterol withdrawal while continuing on carvedilol and belcometasone 264 
[24]. Compared to baseline, carvedilol produced a 1% change in R20, 21% in R5, 265 
59% in X5, and 135% in AX. After formoterol cessation, only AX was associated with 266 
a further significant change amounting to a 210% increase from baseline. Hence 267 
large airways are not involved in beta-2 receptor mediated effects since R20 did not 268 
significantly alter in response to either addition of beta-2 antagonist or removal of 269 
beta-2 agonist. Furthermore the signal to noise ratio for bronchoconstriction with IOS 270 
was calculated as the standardised response mean, which is the ratio of the mean 271 
divided by the standard deviation, with a value of ≥0.8 indicating a sensitive test. The 272 
highest value was observed with AX at 1.74 versus R5 at 0.72, as compared to a 273 
value of 2.08 for FEV1. Thus measuring peripheral lung compliance as AX might be 274 
useful at detecting subtle changes in lung function in COPD, perhaps as a screening 275 
tool in early stage disease or to monitor long term decline. Nonetheless we would 276 
advocate that IOS should be used in conjunction with spirometry in order to make a 277 
comprehensive assessment of a given patient.  278 
 279 
Future directions for IOS research: 280 
 281 
There are fundamental gaps in the literature which warrant further investigation. 282 
Large prospective data sets are required to look at the possible predictive value of 283 
IOS for future moderate to severe exacerbations in high risk patients in GOLD 284 
groups C/D. Such studies should evaluate if lung stiffness (as AX) is more predictive 285 
than FEV1 or FVC. 286 
Given the apparent lack of involvement of large airways (as R20) in mediating 287 
bronchodilator responses in COPD, it would seem logical to perform randomised 288 
controlled trials to investigate the impact of extra fine particle (ie<2um) inhaler 289 
formulations to see if putative improvements in small airway indices such as AX and 290 
R5-R20 might translate into superior longer term reductions in exacerbations, as 291 
compared to larger particle formulations. 292 
Since there is a  relatively poor signal with spirometry in COPD, IOS might prove to 293 
be more sensitive at detecting subtle differences in response to either bronchodilator 294 
or anti-inflammatory therapy, in order to explain commensurate reductions in 295 
exacerbations, improved symptoms and health status.  296 
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It also remains to be seen if IOS might be more suitable than spirometry for detecting 297 
early stage lung damage in COPD. Reference values and minimal important 298 
differences for IOS in COPD are required for use in clinical practice and 299 
interventional trials.   300 
We believe the so called airway oscillometry (AOS) Tremoflo system (Thorasys, 301 
Montreal ,Canada) which uses a novel vibrating mesh, may fulfil the requirement for 302 
a more portable less expensive user friendly device. In turn this may make it more 303 
widely adopted in everyday clinical practice among adult pulmonologists. 304 
 305 
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67 year old female, ex-smoker; COPD; BMI 23, FEV1 0.56L (31% predicted). IOS 436 
values are as follows: Resistance at 5Hz (R5) 0.85 kPa/l/s; Resistance at 20Hz (R20) 437 
0.47 kPa/l/s; Heterogeneity of resistance between 5 and 20Hz (R5-R20) 0.38 kPa/l/s; 438 
Reactance at 5Hz (X5) -1.00 kPa/l/s; Area under the curve reactance (AX) 11.71 439 
kPa/l; Resonant frequency (Fres). 440 
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Abstract  39 
 40 
Impulse oscillometry (IOS) is the most commonly used type of forced oscillation 41 
technique in clinical practice, although relatively little is known about its application in 42 
COPD.  Resistance at 20Hz (R20) is unrelated to COPD severity and does not 43 
improve with bronchodilatation or bronchoconstriction, inferring a lack of large airway 44 
involvement in COPD. Peripheral airway resistance expressed as frequency 45 
dependent heterogeneity between 5Hz and 20Hz (R5-R20), and peripheral airway 46 
compliance as area under the reactance curve (AX), are both closely related to 47 
COPD severity and exacerbations.  Both R5-R20 and AX markedly improve in 48 
response to long acting bronchodilators, while AX appears to be more sensitive than 49 
R5-R20 in response to bronchoconstriction. 50 
Future studies may be directed to assess if IOS in combination with spirometry is 51 
more sensitive at predicting future exacerbationsis superior to spirometry in 52 
predicting future exacerbations.  Perhaps AX might also be useful as a screening tool 53 
in early stage disease or to monitor long term decline in COPD.  54 
 55 
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Abbreviations: 76 
 77 
AX: Area Under reactance curve between 5Hz and resonant frequency 78 
COPD: Chronic obstructive pulmonary disease 79 
FEF25-75: Forced expiratory flow between 25 and 75% 80 
FEV1: Forced expiratory volume in 1 second 81 
FVC: Forced vital capacity 82 
FOT: Forced oscillation technique 83 
Fres: Resonant Frequency 84 
GOLD: Global Initiative for Chronic Obstructive Lung Disease 85 
HRCT: High resolution CT scanning  86 
IOS: Impulse oscillometry 87 
R: Resistance  88 
R5: Resistance at 5Hz 89 
R20: Resistance at 20Hz  90 
R5-R20: Heterogeneity of resistance 91 
SRM: Standardised response mean 92 
X: Reactance  93 
X5: Reactance at 5Hz 94 
Z: Impedance 95 
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 112 
 113 
Background: 114 
 115 
Current COPD guidelines advocate using spirometry to assess airflow limitation in 116 
conjunction with symptoms and exacerbation history [1]. Spirometry involves a forced 117 
expiratory manoeuvre to measure dynamic lung volumes and expiratory flow. It has 118 
no comparable manoeuvre in real life, and hence is an artificial action. Cooperation 119 
may be difficult especially in patients who are breathless or susceptible to coughing. 120 
The forced expiratory flow between 25 and 75% (FEF25-75) of forced vital capacity 121 
(FVC) is thought to represent dynamic volume dependent small airway closure, but 122 
has marked inherent variability. Hence there is an unmet need for an alternative 123 
more patient friendly method to assess lung function in patients with COPD. 124 
The forced mono-frequency oscillation technique (FOT) was first described  in 1956 125 
by Dubois [2] . Since then several FOT methods have been developed of which 126 
impulse oscillometry (IOS) is most commonly used in every day clinical practice. The 127 
application of IOS has been extensively described in asthma [3] .The purpose of this 128 
article is to critically appraise the potential role of IOS in COPD, where much less is 129 
known. It will focus on the more clinical applications of IOS, as this appertains to the 130 
general pulmonologist. This review will therefore not detail the physics of IOS or 131 
other FOT methods which have been covered elsewhere [4-6].  132 
 133 
Basic principles of impulse oscillometry:  134 
 135 
The currently used method of IOS was originally  detailed in 1976 by Michaelson [7] 136 
and was then commercialised in 1998 [8] , available as the Jaeger Masterscreen IOS  137 
(Hoechberg ,Germany) .It has been widely adopted in paediatric pulmonology, but 138 
less so for adults ,aside as a research tool . IOS propagates a train of bi-directional, 139 
harmonic sound waves along the bronchial tree, from a source such as a 140 
loudspeaker. The oscillations are applied at a fixed square wave frequency of 5Hz, 141 
from which all other frequencies of interest are derived, typically multiples of 5Hz 142 
(between 5 and 35Hz) [9], each impulse lasting between 30 to 40ms . Measurements 143 
are made via a conducting tube to a mouthpiece with the cheeks held to obviate 144 
upper airway shunting. Forced oscillations are superimposed on top of tidal breathing  145 
to assess the frequency (Hz) dependence of the pressure/flow (as kPa/L/s or 146 
cmH2O/L/s) relationship of respiratory impedance (Z), as in phase resistance (R) and 147 
out of phase reactance (X) components. A transducer attached to a 148 
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pneumotachograph measures inspiratory and expiratory flow and pressure with 149 
signal filtering used to separate breathing patterns from pressure and flow. It is 150 
performed using normal tidal breathing over a period of around 30 to 40s, and being 151 
effort independent is more physiological than spirometry. Conventionally the mean of 152 
whole breath values are used rather than separate inspiratory and expiratory 153 
moieties. As in spirometry three technically acceptable IOS manoeuvres are used. 154 
In essence, IOS can be considered as bronchial sonar. Higher frequency waves 155 
travel shorter distances typically reflecting larger airways. Thus the resistance at 156 
20Hz (R20) represents proximal resistance. Lower frequency waves travel further 157 
reaching the smaller airways <2mm in diameter after the eighth generation .Hence 158 
the resistance at 5Hz (R5) represents the total lung resistance. COPD and asthma 159 
will increase total resistance (R5) to a relatively greater degree than proximal 160 
resistance (R20). This is known as a frequency dependent change or heterogeneity 161 
of resistance evident as raised peripheral resistance (R5-R20). Nonetheless further 162 
validation is required to characterise heterogeneity of resistance and its relationship 163 
to the calibre of small and large airways.  164 
Reactance can be considered as the out of phase component of respiratory 165 
impedance (with flow, but not volume), reflecting the balance between inertial and 166 
elastic properties of distensible airways. Typically this is measured at 5Hz (X5) or as 167 
the area under the reactance curve (AX) between 5Hz and the resonant frequency 168 
(RF),the latter representing the point at which opposing inertial and capacitive 169 
components cancel each other out . Conventionally AX is reported as a positive 170 
value for the area under the curve, even though in reality reactance per se becomes 171 
more negative (figure). AX represents low frequency reactance in smaller airways 172 
where elastance exceeds inertance, with increased values reflecting reduced lung 173 
compliance and stiffer lungs (Table). In asthma resistance and reactance tend to 174 
change in proportionate fashion, while in COPD reactance usually alters to a 175 
relatively greater degree than resistance. 176 
IOS therefore provides more detailed information than spirometry on regional lung 177 
function and should be considered as being complementary to spirometry to 178 
comprehensively assess lung function in COPD. For example in patients with 179 
persistent asthma who had a preserved FEV1, the combined use of R5-R20  with 180 
FEF25-75 results in more predictive of impaired  long term asthma control than either 181 
parameter used alone [10]. Although there are no defined reference values for 182 
COPD, we would propose pragmatic IOS cut offs for R5 > 0.5 kPa/L/s (>5.1 183 
cmH2O/L/s), R5-20 > 0.10 kPa/L/s (1.02 cmH2O/L/s), AX > 1.0 kPa/L 184 
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(>10.2cmH2O/L) as being abnormal [11, 12]. Further cohort based studies are 185 
required to define proper reference values for COPD and asthma.  186 
 187 
 188 
Relationship of IOS to disease severity: 189 
 190 
The largest database involving IOS was the ECLIPSE cohort comprising  2054 191 
patients with COPD (GOLD stage 2-4) and 233 healthy controls , in whom high 192 
resolution CT scanning (HRCT) was also performed [11]. R20 values were similar 193 
across GOLD stages 2-4 (0.29, 0.31, 0.31 kPa/L/s), but higher than controls (0.26 194 
kPa/L/s). In contrast R5-R20 increased proportionately from GOLD stage 2 -4 (0.15, 195 
0.20, 0.24 kPa/L/s), compared to controls (0.07kPa/L/s) .This in turn suggests that 196 
smaller rather than larger airways are the main determinant of increased lung 197 
resistance.  198 
For AX there were increasing values across GOLD stages 2-4 (1.37, 2.25, 3.23 199 
kPa/L) which were also higher than controls (0.38 kPa/L) along with a similar pattern 200 
for X5. Comparing GOLD 2 versus 4, equated to a 136% difference in AX and 60% in 201 
R5-20. Hence increased reactance (i.e. reduced compliance) predominates over 202 
increased resistance in relation to increasing COPD severity. There was a poor 203 
degree of correlation between R5-R20 or AX and HRCT low attenuation, inferring 204 
that the degree of emphysema is not closely related to either resistance or 205 
compliance.  206 
In a cohort of 215 patients GOLD stages 1-4 ,values for AX (0.66 ,1.43 ,2.07, 2.5 207 
kPa/L) mirrored the ratio of residual volume to total lung capacity (RV/TLC) 208 
(45.7,51.2,58.1,66.0 %) ,inferring the degree of air trapping is related to reduced lung 209 
compliance [12]. Studies have also shown a relationship between increasing AX and 210 
exacerbation frequency in COPD [11, 12]. A cross sectional evaluation of  94 COPD 211 
patients with moderate COPD revealed the strongest relationships for X5 in relation 212 
to FEV1  and specific airway conductance [13]. Multiple regression analysis of 75 213 
patients with moderate COPD found that R5-R20 and X5 but not R20 were more 214 
closely related to health status and symptoms than either FEV1 or HRCT low 215 
attenuation [14] .In a screening study to detect early COPD , among 124 subjects 216 
who had positive  spirometry criteria ,the presence of self reported symptoms was 217 
associated with higher values of R5-R20 ,X5 and AX [15].  218 
A comparison of  36 asthma patients ,24 COPD patients and 24 healthy subjects 219 
showed values for R5-R20 and X5 in severe asthma were 0.13 kPa/L/s and -0.18 220 
kPa/L/s respectively ; in moderate COPD  0.22 kPa/L/s and X5 -0.27 kPa/L ; and in 221 
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controls 0.01 kPa/L/s and  -0.12 kPa/L/s [16]. Thus, patients with COPD have a 222 
relatively higher level of peripheral airway dysfunction compared to those with 223 
asthma in respect of both resistance and reactance. This is in keeping with 224 
pathological and radiological changes seen in small airways associated with disease 225 
progression in COPD [17, 18] . 226 
 227 
Bronchodilator response and IOS: 228 
 229 
Significantly greater changes were observed for R5 and RF, but not R20 or X5, when 230 
comparing responses to tiotropium 18ug and salmeterol 100ug in 32 patients with 231 
moderate COPD [19] . A trial in 16 patients with moderate COPD evaluated the 232 
effects of 4 weeks with open label tiotropium alone or with the addition of tulobuterol . 233 
Tiotropium alone produced significant improvements versus baseline in AX, R5 and 234 
R5-20, both drugs were better than tiotropium ,while R20 was unchanged [20] . For 235 
example with both drugs there were 56% ,46%  and 38%  changes  in AX ,X5  and 236 
R5-R20 respectively,  as compared to a 16% change in FEV1.  237 
In an open label study 20 patients with moderate COPD received either tiotropium or 238 
glycopyrronium/indacaterol with IOS measured at baseline and 52 weeks [21] . 239 
Compared to baseline there were significant changes in R5, X5 but not R20 with 240 
glycopyrronium /indacaterol, while tiotropium afforded no improvements.  241 
A double blind randomised cross-over trial involved 19 patients with severe COPD 242 
who received tiotropium or placebo for 2 weeks as add on to budesonide/formoterol 243 
combination taken during the preceding 4 weeks[22] . Compared to placebo the first 244 
but not last dose of tiotropium as triple therapy conferred significant improvements in 245 
X5, AX and RF, but not R5 or R20. Specific airways resistance but not RV/TLC also 246 
improved after single but not chronic dosing with tiotropium. 247 
Taken together these data suggest that muscarinic and beta-2 receptors located in 248 
small airways (R5-R20, X5, AX) are relatively more important than large airways 249 
(R20) for mediating bronchodilator responses in COPD. Alternatively one might 250 
speculate that large airways disease per se is less important than small airway 251 
disease in COPD.  Moreover increased lung compliance (as reduced AX values) in 252 
response to bronchodilators may reflect lung deflation, perhaps allowing the patient 253 
to breathe at a better mechanical advantage at a lower RV. 254 
 255 
Bronchoconstrictor response with IOS: 256 
 257 
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Methacholine challenge was performed in 10 asthma and 25 moderate to severe 258 
COPD patients to achieve a 20% fall in FEV1. In asthma there was concordance 259 
between effects on resistance and reactance ,as a significant fall in X5 along with a 260 
significant rise in R5 , while in COPD there was discordance in terms of a significant  261 
change in X5 but not R5 [23] .  262 
12 moderate to severe COPD patients receiving beclometasone/formoterol 263 
combination at baseline were given the non selective beta-blocker carvedilol 264 
,followed by formoterol withdrawal while continuing on carvedilol and belcometasone 265 
[24]. Compared to baseline, carvedilol produced a 1% change in R20, 21% in R5, 266 
59% in X5, and 135% in AX. After formoterol cessation, only AX was associated with 267 
a further significant change amounting to a 210% increase from baseline. Hence 268 
large airways are not involved in beta-2 receptor mediated effects since R20 did not 269 
significantly alter in response to either addition of beta-2 antagonist or removal of 270 
beta-2 agonist. Furthermore the best signal to noise ratio for bronchoconstriction with 271 
IOS was calculated expressed as the highest standardised response mean, which is 272 
the ratio of the mean divided by the standard deviation, with a value of ≥0.8 273 
indicating a sensitive test.  The highest value was observed with AX at 1.74 versus 274 
R5 at 0.72, as compared to a value of 2.08 for FEV1. Thus measuring peripheral 275 
lung compliance as AX might be useful at detecting subtle changes in lung function 276 
in COPD, perhaps as a screening tool in early stage disease or to monitor long term 277 
decline. Nonetheless we would advocate that IOS should be used in conjunction with 278 
spirometry in order to make a comprehensive assessment of a given patient.  279 
 280 
Future directions for IOS research: 281 
 282 
There are fundamental gaps in the literature which warrant further investigation. 283 
Large prospective data sets are required to look at the possible predictive value of 284 
IOS for future moderate to severe exacerbations in high risk patients in GOLD 285 
groups C/D. Such studies should evaluate if lung stiffness (as AX) is more predictive 286 
than FEV1 or FVC. 287 
Given the apparent lack of involvement of large airways (as R20) in mediating 288 
bronchodilator responses in COPD, it would seem logical to perform randomised 289 
controlled trials to investigate the impact of extra fine particle (ie<2um) inhaler 290 
formulations to see if putative improvements in small airway indices such as AX and 291 
R5-R20 might translate into superior longer term reductions in exacerbations, as 292 
compared to larger particle formulations. 293 
9 
 
Since there is a  relatively poor signal with spirometry in COPD, IOS might prove to 294 
be more sensitive at detecting subtle differences in response to either bronchodilator 295 
or anti-inflammatory therapy, in order to explain commensurate reductions in 296 
exacerbations, improved symptoms and health status.  297 
It also remains to be seen if IOS might be more suitable than spirometry for detecting 298 
early stage lung damage in COPD. Reference values and minimal important 299 
differences for IOS in COPD are required for use in clinical practice and 300 
interventional trials.   301 
We believe the so called airway oscillometry (AOS) Tremoflo system (Thorasys, 302 
Montreal ,Canada) which uses a novel vibrating mesh, may fulfil the requirement for 303 
a more portable less expensive user friendly device. In turn this may make it more 304 
widely adopted in everyday clinical practice among adult pulmonologists. 305 
 306 
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Figure Legend: 436 
67 year old female, ex-smoker; COPD; BMI 23, FEV1 0.56L (31% predicted). IOS 437 
values are as follows: Resistance at 5Hz (R5) 0.85 kPa/l/s; Resistance at 20Hz (R20) 438 
0.47 kPa/l/s; Heterogeneity of resistance between 5 and 20Hz (R5-R20) 0.38 kPa/l/s; 439 
Reactance at 5Hz (X5) -1.00 kPa/l/s; Area under the curve reactance (AX) 11.71 440 
kPa/l; Resonant frequency (Fres). 441 
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Table.  
 
Comparison of spirometry and IOS in COPD 
 
 Spirometry  IOS 
Outputs  FEV1,FVC ,FEF25-75 R5, R20, X5, AX, RF 
Signal to noise  ratio + + 
Patient friendly    - + 
Breathing pattern Forced expiratory  Tidal  
Reference values for 
COPD 
+ - 
Large/small airways  +/- + 
Cost  + - 
Portability  + - 
FDA approved  + + 
 
FEV1 :forced expiratory volume in 1s ,FVC :forced vital capacity ,FEF25-75:forced 
expiratory flow between 25 and 75% of FVC , R5 :resistance at 5Hz ,resistance at 
20Hz ,X5 :reactance at 5Hz ,AX :area under reactance curve , RF :resonant 
frequency .Both methods should be used in complimentary fashion to fully assess 
lung function . 
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